Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
July 1, 2021

LoA Update: India Globalization Capital’s Alzheimer’s disease cannabinoid-based treatment sees 15-point boost in chances to advance to next stage after Phase I completion

India Globalization Capital’s IGC-AD1 for Alzheimer’s disease (AD) symptoms saw its Phase Transition Success Rate (PTSR) surge 15 points to 73% after completing its Phase I trial.

By William Newton

India Globalization Capital’s IGC-AD1 for Alzheimer’s disease (AD) symptoms saw its Phase Transition Success Rate (PTSR) surge 15 points to 73% after completing its Phase I trial. The PTSR update occurred on 25 June after IGC announced on 23 June it completed the final cohort of its 12-patient Phase I. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

The multiple ascending dose Phase I trial (NCT04749563) has a primary endpoint assessing safety, and changes in the Neuropsychiatric Inventory (NPI) scale as a secondary efficacy endpoint. IGC-AD1, which uses the psychoactive component of cannabis THC, is designed to help improve the lifestyle of patients with AD.

Phase I completion also generated a modest 2-point bump in the drug’s Likelihood of Approval (LoA), which rose to 9%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. It is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

IGC has a market cap of $67.6m.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy